Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery
The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.
Age ≥18 years [+8]
ALT >3-fold the upper limit of normal [+10]